DOCSLIB.ORG

Anti-Inflammatory Drugs Amy J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Inflammatory Drugs Amy J Anti-Inflammatory Drugs Amy J. Rankin Diplomate ACVO Associate Professor Ophthalmology Kansas State University • Corticosteroids • NSAIDs Corticosteroids • Adrenal gland • Glucocorticoids – Zona fasciculata – Zona reticularis – Anti-inflammatory – Metabolic – Immune • Mineralocorticoids – Zona glomerulosa www.news-medical.net – Electrolyte & water balance Riviere & Papich, Veterinary Pharmacology & Therapeutics, 10th Ed Glucocorticoids • Anti-inflammatory – Inhibition of angiogenesis – Reduces leukocyte migration – Decreased capillary permeability – Decreases WBC degranulation • Effects on tissue regeneration – Decreased fibroblastic & collagen formation – Increased collagenolytic activity – Decreased wound healing • Loewenberg et al.,Trends Molec Med, 2007 Loewenberg et al., Trends Molec Med, 2007 Glucocorticoids-Transrepression • GC binds to receptor in cytoplasm • GC-receptor translocates to nucleus • Binds to negative GRE • Down regulation of pro-inflammatory proteins (IL-1 & IL-2) Glucocorticoids-Transrepression • GC binds to receptor in cytoplasm • GC-receptor interacts with transcription factors (TF) NF- ĸβ, AP-1 • GC-receptor complex or TFs do not bind to pro- inflammatory GREs • Down regulation of pro-inflammatory and immune stimulation factors Glucocorticoids-Transrepression • GC binds to receptor in cytoplasm • GC-receptor translocates to the nucleus • GC-receptor binds to nuclear coactivators – AP-1 • Inhibition of pro-inflammatory protein proteins Glucocorticoids-Transactivation Stahn et al., Molecular and Cellular Endocrinology, 2007) • GC diffuses through cell membrane • GC binds to receptor in cytoplasm • GC-receptor translocates to nucleus • Binds to GC response element (GRE) in target gene • Up-regulation of anti-inflammatory, immunomodulatory, and metabolic processes Non-genomic MOA • High dose therapy • Rapid onset of clinical effects – Anti-inflammatory – Immunosuprression Non-genomic MOA • GC interact with cellular membranes – Reduced Ca and Na transport across membranes of immune cells – Rapid immunosuppression Non-genomic MOA University of Tokyo • GC-receptor binding causes protein complex dissociation so GC-receptor translocates to nucleus • Heat shock proteins & kinases that are released mediate various rapid intracellular effects • GC-receptor inhibits release of AA from plasma membrane via transcription-independent mechanism Non-genomic MOA • GC effects mediated by a membrane- bound GC receptor • Upregulation of membrane GC receptor during immunostimulation • GC-induced membrane bound GC receptor-mediated apoptosis Anti-inflammatory Effects of Glucocorticoids • Inhibition – Pro-inflammatory transcription factors • AP-1 • NF- ĸβ • STAT – Expression of pro-inflammatory cytokines • IL1-6, IL 11-13, IL 16, & IL 17 • Interferon –γ • TNF • GM-CSF Anti-inflammatory Effects of Glucocorticoids • Synthesis – Anti-inflammatory proteins • Lipocortin – Inhibits phospholipase A2 • IL-10 • Annexin-1 • Mitogen-activated protein kinase phosphatase-1 – Decreased transcription of pro-inflammatory genes Immunosuppressive Effects of Glucocorticoids • Decrease number and function of B &T cells – Inhibition of NF-ĸβ • Induction of TGF-β expression – Blocks cytokine synthesis and T-cell activation • Inhibition of humoral immunity – Decreased synthesis of IL-2 & IL-2 receptors • Inhibition of cell-mediated immunity – Inhibition of multiple interleukins (IL-1, IL-2, IL-3, IL-6) GC Side Effects • Systemic – Gluconeogenesis – Breakdown of muscle – Effects on psyche – Diabetogenic – Suppression of HPAA – Osteoporosis – PU/PD • Inhibition of ADH release and action GC Side Effects • Ophthalmic – Cataract – Ocular hypertension – Decreased wound healing – Potentiate infection – Corneal lipid deposition GC-Induced Cataract • Humans posterior subcapsular cataracts • Oral, topical, cutaneous, inhalation... • Dose and duration dependent • Children more sensitive • Reported prevalence 22% – 0-90% GC-Induced Cataract • Not well documented in SA • Experimentally-induced cats – Topical dexamethasone NaP or prednisolone – Subscapular cataracts after 40 days of therapy Zhan et al., Experimental Eye Research, 1992 Etiology of GC-Induced Cataract • Etiology of GC-induced cataract – Unknown – Decrease in lens enzymes – Alterations in lens hydration • Modulation of NaKATPase – Aberrant posterior LEC migration – Alteration in ocular growth factors? GC Ocular Hypertension • Systemic, periocular, topical, inhalational routes... • High responder – 15 mmHg increase • Moderate responder – 6-15 mmHg increase Phulke S et al., J Curr Glaucoma Practi 2017 Becker B, Invest Ophthalmol, 1965 Becker B & Chevette L, Am J Ophthalmol, 1964 Becker B & Hahnka L, Am J Ophthalmol, 1964 GC Ocular Hypertension • Generally reversible • Risk factors in humans: – Glaucoma suspects (30%) – POAG patients (90%) – High myopia – History of refractive surgery – Bimodal age distribution (<10 years and older adults) – Diabetes mellitus – Genetics Morales J & Good D, J Cataract Refract Surg, 1998 Podos SM et al., Am J Ophthalmol, 1966 Armaly MF, Arch Ophthalmol, 1963 Becker B, Am J Ophthalmol, 2971 Etiology of GC Hypertension • Decrease in outflow facility • Accumulation of extracellular material in the TM • Increased expression laminin & myocilin TM cells • Activation of GC receptors in TM • Increased type IV collagen, heparin sulfate proteoglycan, fibronectin Clark AF et al, Invest Opthalmol Vis Sci, 2001 Johnson et al., Arch Ophthalmol, 1997 Dickerson JE et al, Exp Eye Res, 1998 Tawara A et al., Glaucoma, 2008 GC Ocular Hypertension-Dogs • Beagles with POAG – 2 weeks topical 0.1% dex QID – Mean IOP increase 5 mmHg – Returned to baseline within 1 week • Normal dogs – Oral hydrocortisone 3.3 mg/kg TID 5 weeks – No significant increase in IOP Gelatt KN & Mackay EO, J Ocul Pharmacol Ther, 1998 Herring IP et al., Vet Ophthalmol, 2004 GC Ocular Hypertension Normal Cats – Topical 0.1% dex or 1% prednisolone TID for 4 weeks – Significant increase in IOP with 2-3 weeks – Mean IOP increase 4.5 mmHg greater than control cats – IOP values quickly returned to normal Bhattacherjee P et al., Arch Ophthalmol, 1999 – Topical 1% dex NaP BID or TID or 1% prednisolone acetate BID – Significant increase IOP that was reversible Zhan G et al., Exp Eye Res, 1992 GC Ocular Hypertension - Cats • 0.1% dexamethasone or 1% prednisolone BID • Normal cats (n=5) – 2/5 increased IOP compared to contralateral eye (maximum 6.4 mmHg) • Feline congenital glaucoma cats (n=11) – 8/11 increased IOP compared to contralateral eye (maximum 56 mmHg) • Mild 3 cats (<15 mmHg) • Moderate 2 cats (15-25 mmHg) • Marked 3 cats (>25 mmHg) • Values returned to baseline within 7-10 days Gosling et al., Vet Ophthalmol, 2016 GC Ocular Hypertension • Normal cows (Herford and Brahman X) • 1% prednisolone TID 7 wks • 100% of cows increased IOP after 3 weeks of therapy (maximum 15 mmHg) • Normal sheep (Corriedale) • 0.5% prednisolone TID 3-4 wks • 100% of sheep increased IOP after 2 weeks (~16 mmHg difference) Gerometta R et al., Arch Ophthalmol, 2004 Gerometta R et al., Inves Ophthalmol Vis Sci, 2009 GC Ocular Hypertension - Cows • Normal cows (Herford and Brahman X) • 1% prednisolone TID • Altered gene expression in TM • Expression of 258 genes upregulated 187 genes downregulated in TM • Genes coding for cytoskeletal proteins, enzymes growth & transcription factors, immune response proteins Danias J et al., Invest Ophthalmol Vis Sci, 2011 GC Corneal Wound Healing • Increase lytic action of collagenase • Delay wound healing • Decreased collagen deposition • Decreased stromal keratocyte proliferation • In vitro dexamethasone phosphate less cytopathic effect on cultured epithelial cells than prednisolone Hendrix DH et al., Vet Ophthalmol, 2002 GC Systemic Side Effects • Suppression of HHAA – Dogs 1% prednisolone QID 2 weeks • Adrenal suppression & liver changes – 0.1% dexamethasone QID OU • Mean 0.03mg/kg of body weight/day • Suppression of ACTH-stimulated cortisol – 2 subconjunctival injections 10 mg methylprednisolone (3 weeks) • Iatrogenic Cushing's disease Eichenbaum J et al., J Am Anim Hosp Assoc,1988 Roberts et al, Am J Vet Res, 1984 Glaze et al., J Am Vet Med Assoc, 1988 Regnier, Res Vet Sci, 1982 Murphy, J Am Animal Hosp Assoc, 1990 GC Systemic Side Effects • Humans topical dexamethasone – Diabetics significant increase in BG at 1 month • Diabetic dogs topical 1% prednisolone acetate – No significant difference in BG curves, fructosamine or clinical scores between diclofenac or prednisolone • Diabetic rats & humans subconjunctival injection dexamethasone – Increased BG Bahr, Curr Eye Res, 2007 Rankin AJ et al., Proc ACVO, 2017 Faukushima, Eye, 2001 Fukushima, J Cataract Refract Surg, 2001 GC Side Effects • Calcific band keratopathy – Humans & horses • Lipid keratopathy?? – Dogs • Bilateral exophthalmos – Calves parenteral dexamethasone – 30 mg/kg BID noted after 28 days Berryhill et al., Vet Ophthalmol, 2017 Brooks, Equine Vet J, 2012 Taravella et al., Arch Ophthalmol, 1994 Townsend et al., Vet Ophthalmol, 2003 Minimize GC Side Effects • Long-circulating liposomal GC • Selective GCR agonists (SERGAs) • Selective GCR modulators (SEGMs) • Sustained action of steroids • Decreased dose • Less frequent dosing interval Liposomal Glucocorticoids • Liposomes – Phospholipid bilayer – GC in lumen – PEG polyethylene glycol • Modification of surface to increase stability and t1/2 • Medial applications – Cancer, RA, asthma, Parkinson’s dz... Liposomal Prednisolone • Human colon carcinoma T-84 cell lines – Direct antiproliferative effect
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant Et Al
    US 20170152273A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant et al. (43) Pub. Date: Jun. 1, 2017 (54) TOPCAL PHARMACEUTICAL Publication Classification FORMULATIONS FOR TREATING (51) Int. Cl. NFLAMMLATORY-RELATED CONDITIONS C07F 5/02 (2006.01) Applicant: A6II 47/06 (2006.01) (71) Anacor Pharmaceuticals Inc., New A69/06 (2006.01) York, NY (US) A6IR 9/00 (2006.01) (72) Inventors: Tejal Merchant, Cupertino, CA (US); A6II 47/8 (2006.01) Dina Jean Coronado, Danville, CA A6II 45/06 (2006.01) (US); Charles Edward Lee, Union A6II 47/10 (2006.01) City, CA (US); Delphine Caroline A6II 3/69 (2006.01) Imbert, Cupertino, CA (US); Sylvia (52) U.S. Cl. Zarela Yep, Milpitas, CA (US) CPC .............. C07F 5/025 (2013.01); A61K 47/10 (2013.01); A61K 47/06 (2013.01); A61K3I/69 (73) Assignee: Anacor Pharmaceuticals Inc., New (2013.01); A61K 9/0014 (2013.01); A61 K York, NY (US) 47/183 (2013.01); A61K 45/06 (2013.01); A61K 9/06 (2013.01); C07B 2.200/13 (21) Appl. No.: 15/364,347 (2013.01) (22) Filed: Nov. 30, 2016 (57) ABSTRACT Related U.S. Application Data (60) Provisional application No. 62/420,987, filed on Nov. Topical pharmaceutical formulations, and methods of treat 11, 2016, provisional application No. 62/260,716. ing inflammatory conditions with these formulations, are filed on Nov. 30, 2015. disclosed. Patent Application Publication Jun. 1, 2017. Sheet 1 of 4 US 2017/0152273 A1 ?zzzzzzzzzzzzzzzzzzzzzzzzzzzz ????????????????????????????????????????????????????????????????????? S&S&S Šx&N Sssssssssssssssssssssssssssssssssssssss (r) eqn. O. peppy jeeNA go eunO/A Patent Application Publication Jun.
    [Show full text]
  • Penetration of Synthetic Corticosteroids Into Human Aqueous Humour
    Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec­ trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu­ orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh­ used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under­ preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou­ available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography).
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs Inhibit Bone Healing: a Review S
    Review Article © Schattauer 2010 385 Non-steroidal anti-inflammatory drugs inhibit bone healing: A review S. Barry Washington State University, Department of Veterinary Clinical Sciences, Veterinary Teaching Hospital, Pullman, Wash- ington, USA crine and autocrine activity, have since Keywords stems from prostaglandin inhibition and is been shown to regulate constitutive and in- Non-steroidal anti-inflammatory drugs, likely multifactorial. In human medicine ducible functions throughout the body, in- NSAID, bone healing NSAID are known to prevent heterotopic ossi- cluding bone healing (5–9). The mech- fication, however the clinical importance of anism of NSAID inhibition to bone healing Summary their effects on bone healing remains contro- is unknown, but is likely multifactorial. Re- The ability of non-steroidal anti-inflammatory versial. Although a small handful of reports searchers have suggested that NSAID affect drugs (NSAID) to inhibit bone healing has suggest that NSAID suppress bone healing in normal bone healing in multiple ways, with been established in experimental animal dogs and horses, there is little published infor- emphasis often (but not exclusively) placed models using mice, rats, and rabbits. The mation to direct veterinary practice in do- on processes related to the inflammatory mechanism of action is largely unknown but mestic species. stage. Deciphering the mechanism of NSAID inhibition requires an understanding of Correspondence to: Vet Comp Orthop Traumatol 2010; 23: 385–392 Sabrina Barry, DVM doi:10.3415/VCOT-10-01-0017 fracture healing. Fracture healing presents Washington State University Received: January 31, 2010 an exquisitely orchestrated series of coor- Department of Veterinary Clinical Sciences Accepted: June 23, 2010 dinated molecular and cellular events.
    [Show full text]
  • Latest Administration Hour Prior to Competition Max Dosage Per Pound of Body Weight Medication Trade Name Medication Generic Name
    MEDICATION MEDICATION MAX DOSAGE PER POUND LATEST ADMINISTRATION HOUR ADMINISTRATION METHOD GENERIC NAME TRADE NAME OF BODY WEIGHT PRIOR TO COMPETITION (single dose per 24 hours unless specified otherwise) Dexamethasone Azium® 2.0 mg/100Lb >12 hours IV, IM (20 mg/1000Lb) or 0.5 mg/100Lb >6 hours IV (5.0 mg/1000Lb) or 1.0 mg/100LB >6 hours Oral (10 mg/1000Lb) Diclofenac Surpass® 5 inch ribbon, 1⁄2 inch thick, >12 hours Topical, 2 doses each day 12 hours apart one site Firocoxib Equioxx® 0.1 mg/kg >12 hours Oral (0.0455 mg/Lb) (45.5 mg/1000Lb) Phenylbutazone (“bute”) * Butazolidin® 2.0 mg/Lb >12 hours Oral, IV (2.0 grams/1000Lb) or 1.0 mg/Lb AM & PM feed Oral, 2 doses each day, 12 hours apart (1.0 grams/1000Lb) Flunixin meglumine * Banamine® 0.5 mg/Lb >12 hours Oral, IV (500 mg/1000Lb) Ketoprofen Ketofen® 1.0 mg/Lb >4 hours, but IV (1.0 gram/1000Lb) >6 hours is recommended Meclofenamic acid Arquel® 0.5 mg/Lb Oral, 2 doses each day, 12 hours apart (500 mg/1000Lb) Naproxen Naprosyn® 4.0 mg/Lb >12 hours Oral (4.0 grams/1000Lb) Eltenac Not yet approved Telzenac® 0.25 mg/Lb (250 mg/1000Lb) 12 hours IV Methocarbamol Robaxin® 5.0 mg/Lb >6 hours Oral, IV, 2 doses each day, 12 hours apart (5.0 grams/1000Lb) * Do not administer phenylbutazone and flunixin at the same time (Unless used according to The maximum treatment time for any of the above permitted medication is five days, with the Section 8).
    [Show full text]
  • [email protected]
    SAFETY DATA SHEET Revision Date 13-Jul-2016 Version 1 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING Product identifier Product Name Pred Forte Other means of identification Product Code FP61 Synonyms Prednisolone Acetate Recommended use of the chemical and restrictions on use Recommended Use Corticosteroid This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient. Details of the supplier of the safety data sheet Manufacturer ALLERGAN 400 Interpace Parkway, Morris Corporate Center III Parsippany, NJ 07054, USA +1-800-272-5525 E-mail address [email protected] Emergency telephone number Emergency Telephone Call CHEMTREC Day or Night Within USA or Canada: 1-800-424-9300 Outside USA and Canada: +1-703-741-5970 (collect calls accepted) 2. HAZARDS IDENTIFICATION Classification OSHA Regulatory Status This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Reproductive toxicity Category 2 Effects on or via lactation Yes Label elements Emergency Overview Danger Hazard statements H362 - May cause harm to breast-fed
    [Show full text]
  • Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle By
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Food Anal. Methods (2016) 9:1837–1848 DOI 10.1007/s12161-015-0352-y Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle by Liquid Chromatography-Tandem Mass Spectrometry Piotr Jedziniak1 & Małgorzata Olejnik1 & Konrad Pietruk1 & Edyta Protasiuk1 & Teresa Szprengier-Juszkiewicz1 & Jan Żmudzki1 Received: 11 February 2015 /Accepted: 4 November 2015 /Published online: 21 November 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract A method for the determination of a wide range Introduction residues of anti-inflammatory drugs (16 acidic non-steroidal anti-inflammatory drugs and four metamizole metabolites and Non-steroidal anti-inflammatory drugs (NSAIDs) and five corticosteroids) has been was developed. In the first step glucocorticosteroids (GCs) are widely used in veterinary medi- of sample preparation, acetate buffer was added to minced cine as well as in treatment of diseases in food-producing ani- muscle samples and 15-min ultrasound-assisted enzymatic mals. Despite its effectiveness, the important drawback of phar- hydrolysis was performed. Next, the samples were extracted macotherapy is drug residues in animal tissues. It became an twice with acetonitrile, freezed and analysed. The analytes important issue in the food safety. Potential toxicity of medicinal were separated on a C18 column with a 25-min gradient of veterinary products has to be evaluated before the drug registra- methanol/acetonitrile (8:2) and 0.05 M ammonium formate at tion. When necessary, maximum residue limits (MRLs) in food pH 5.0 and determined by liquid chromatography-tandem are established.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • W W W .Bio Visio N .Co M New Products Added in 2020
    New products added in 2020 Please find below a list of all the products added to our portfolio in the year 2020. Assay Kits Product Name Cat. No. Size Product Name Cat. No. Size N-Acetylcysteine Assay Kit (F) K2044 100 assays Human GAPDH Activity Assay Kit II K2047 100 assays Adeno-Associated Virus qPCR Quantification Kit K1473 100 Rxns Human GAPDH Inhibitor Screening Kit (C) K2043 100 assays 20 Preps, Adenovirus Purification Kit K1459 Hydroxyurea Colorimetric Assay Kit K2046 100 assays 100 Preps Iodide Colorimetric Assay Kit K2037 100 assays Aldehyde Dehydrogenase 2 Inhibitor Screening Kit (F) K2011 100 assays Laccase Activity Assay Kit (C) K2038 100 assays Aldehyde Dehydrogenase 3A1 Inhibitor Screening Kit (F) K2060 100 assays 20 Preps, Lentivirus and Retrovirus Purification Kit K1458 Alkaline Phosphatase Staining Kit K2035 50 assays 100 Preps Alpha-Mannosidase Activity Assay Kit (F) K2041 100 assays Instant Lentivirus Detection Card K1470 10 tests, 20 tests Beta-Mannosidase Activity Assay Kit (F) K2045 100 assays Lentivirus qPCR Quantification Kit K1471 100 Rxns 50 Preps, Buccal Swab DNA Purification Kit K1466 Maleimide Activated KLH-Peptide Conjugation Kit K2039 5 columns 250 Preps Methionine Adenosyltransferase Activity Assay Kit (C) K2033 100 assays CD38 Activity Assay Kit (F) K2042 100 assays miRNA Extraction Kit K1456 50 Preps EZCell™ CFDA SE Cell Tracer Kit K2057 200 assays MMP-13 Inhibitor Screening Kit (F) K2067 100 assays Choline Oxidase Activity Assay Kit (F) K2052 100 assays Mycoplasma PCR Detection Kit K1476 100 Rxns Coronavirus
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs As Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals
    Annual Research & Review in Biology 26(1): 1-13, 2018; Article no.ARRB.40829 ISSN: 2347-565X, NLM ID: 101632869 Non-Steroidal Anti-Inflammatory Drugs as Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals Bianca F. Bishop1 and Suong N. T. Ngo1* 1School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia. Authors’ contributions This work was carried out in collaboration between both authors. Author BFB performed the collection and analysis of the data. Author SNTN designed the study, managed the analyses and interpretation of the data and prepared the manuscript. Both authors read and approved the final manuscript. Article Information DOI: 10.9734/ARRB/2018/40829 Editor(s): (1) David E. Martin, Martin Pharma Consulting, LLC, Shawnee, OK, USA. (2) George Perry, Dean and Professor of Biology, University of Texas at San Antonio, USA. Reviewers: (1) Fulya Ustun Alkan, Istanbul University, Turkey. (2) Thompson Akinbolaji, USA. (3) Ramesh Gurunathan, Sunway Medical Center, Malaysia. (4) Mohamed Ahmed Mohamed Nagy Mohamed, El Minia Hospital, Egypt. Complete Peer review History: http://www.sciencedomain.org/review-history/24385 Received 10th February 2018 Accepted 21st April 2018 Review Article Published 30th April 2018 ABSTRACT Aims: This study aims to systematically review currently available data on the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of cancer in domestic animals to evaluate the efficacy of different treatment protocols and to suggest further recommendations for future study. Methodology: Literature data on the use of NSAIDs in domestic animals as chemo-preventive agents in the last decade were collected and critically reviewed.
    [Show full text]
  • Prednisolone Also Binds to Transcortin • Other Synthetic GS Only Bind to Albumin
    PK/PD considerations for corticosteroids P L Toutain, National Veterinary School, Toulouse, France Wuhan October 2015 1 Anti-inflammatory drugs Corticosteroids NSAIDs 2 Glucocorticoids: main properties • Glucocorticosteroids (GCS) are broad and potent anti- inflammatory drugs. • They are extensively used to mitigate or suppress inflammation associated with a variety of conditions especially joint and respiratory system inflammation. • GCs are not curative: • GCs are only palliative symptomatic treatments and chronic use of GCs can be, in fine , detrimental • GCs possess many other pharmacological properties (not reviewed in this presentation) 3 The cortisol or hydrocortisone 4 Cortisol : An endogenous hormone and a surrogate endpoint of the duration of the GCS effects; it physiology should be understood to use properly GCS 5 Cortisol synthesis • All GCs used in therapeutics are synthetic derivatives of cortisol. • Cortisol (hydrocortisone) is synthesized in the adrenal cortex and it is the main corticosteroid hormone in most species. 6 Steroids synthesis by the adrenal gland Aldosterone Cortisol Androgens Epinephrine (adrenalin) 7 Cortisol ou Hydrocortisone structure – activity relationship Three structural properties are required for a GC activity (i.e. for cortisol to bind to GC receptor) 8 Cortisol (hydrocortisone) • Minimal information on cortisol physiology (secretion, distribution & elimination ) needs to be known to understand the clinical pharmacology of GCS 9 Plasma cortisol • Cortisol levels are very different in domestic species • Pattern of secretion – Circadian rhythm (h) – Pulsatilty (minute) 10 Plasma cortisol level Plasma concentration (ng/mL) 600 500 400 300 Series1 200 100 0 1 2 3 4 5 11 Plasma cortisol levels: circadian rhythm & pulsatility Toutain et al. Domestic.Anim.Endocrinol.
    [Show full text]
  • The Pathophysiology of Pain, Our Veterinary Patients, and You… What Can Or Should Be Done?
    The Pathophysiology of Pain, Our Veterinary Patients, And you… What Can or Should Be Done? Andrew Claude DVM, Dipl ACVAA Michigan State University College of Veterinary Medicine [email protected] Objectives • Definitions. • Process of Nociception. • What is pain? • AVMA/ACVAA regarding pain. • Patient – client considerations • Pain management in medicine • Clinical signs of pain in dogs/cats • Preemptive analgesia options • Pain scores in dogs and cats (if time) Definitions • Anesthesia = analgesia = analgesic? Clinician's Brief • General anesthesia: General vs. local and regional anesthesia • Analgesia: the inability to feel pain • Analgesic: any member or group of drugs used to achieve analgesia or relief from pain. • Analgesia →Nociception • Acute vs. Chronic pain, neuropathic pain Process of nociception • Transduction • Aβ, Aδ, c-Fibers, silent • Transmission • Dorsal horn, CNS • Primary Modulation • Segmental reflexes • Projection • Perception • Conscious Pain • Autonomic (SNS) • Memory • Emotions • Central/peripheral • Humans/animals What is pain? • Definition: “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage.” • Sensory component (nociception) • Affective component (experience) • Considered the 5th clinical sign • HR • RR • Temp • BP • Pain assessment What is pain? • Requires conscious perception of a noxious event • Do unconscious patients perceive pain? • Nociception: “the neurophysiological process whereby noxious mechanical, chemical, or thermal stimuli are transduced into electrical signals (action potentials) by high-threshold nociceptors.” These action potentials follow a series of pathways that ultimately end in the brain • The conscious result is “pain” AVMA • Pain in Animals • Animal pain is a clinically important condition that adversely affects an animal's quality of life. Drugs, techniques, or husbandry methods should be used to prevent, minimize, and relieve pain in animals experiencing or expected to experience pain.
    [Show full text]